Vertex Pharmaceuticals will head to US regulators after its immunoglobulin A nephropathy (IgAN) drug povetacicept was successful in a Phase III trial. The ongoing Phase III RAINER trial (NCT06564142) met its primary endpoint, with patients treated with 80... See more
Roche’s oral selective oestrogen receptor degrader (SERD) has failed to meet its primary endpoint in a Phase III breast cancer trial. In the persevERA Breast Cancer study (NCT04546009), giredestrant was investigated in combination with Pfizer’s Ibrance (p... See more
Pregnant and breastfeeding women have historically been excluded from medical research, resulting in substantial gaps in evidence on the safety and efficacy of medicines and vaccines. Analysis led by the Global Observatory on Health Research and Developme... See more
The European Medicines Agency (EMA) has released draft guidance for sponsors conducting clinical trials during public health emergencies (PHEs). The guidance, published through the Accelerating Clinical Trials in the European Union (ACT EU) initiative, ou... See more
The UK’s National Health Service (NHS) has been awarded £47.8m ($63.8m) from the National Institute for Health and Care Research (NIHR) to pay for equipment that will increase the NHS’s ability to deliver high-quality clinical trials. The award, which is ... See more
